May 31 Financial Quick Takes: Mabpharm prices Hong Kong IPO; plus follow-ons from Amicus, Myovant and more

Mabpharm down in first day of Hong Kong trading
Mabpharm Ltd. (HKSE:2181) lost HK$0.29 to HK$1.21 in its first day of trading Friday after raising HK$1.2 billion ($149.7 million) in a Hong Kong IPO Thursday that valued the biosimilars company at HK$6.2 billion ($788.1 million). Mabpharm sold 783.6 million shares in the IPO at HK$1.50, the bottom of its proposed range of HK$1.50-HK$1.95 (see "Biosimilars Company Mabpharm Sets Sights on Hong Kong IPO").

Amicus raises $175M after UPenn deal expansion
Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $175 million late Thursday through the sale of 16.3 million shares at $10.75 in an upsized follow-on underwritten by J.P. Morgan, Goldman Sachs and SVB Leerink. Amicus, which had proposed to raise $150 million, added three more rare disease gene therapy programs earlier this week via an expansion of its deal with the University of Pennsylvania (see "Amicus Bolsters Rare Disease Gene Therapy Pipeline with Expanded UPenn Deal")...